Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lev Pharmaceuticals Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.levpharma.com

Latest From Lev Pharmaceuticals Inc.

Matthew Duffy joins CorMedix board

CorMedix, a pharmaceutical company developing and commercialising therapeutic products for the prevention and treatment of cardiorenal disease, has appointed Matthew Duffy to its board of directors. Having previously worked for Pfizer, MedImmune, and Lev Pharmaceuticals, Mr Duffy is currently a managing partner and founder of Black Diamond Research which provides consulting services to industry.

Will Shire's acute HAE drug OK shift dynamic for ViroPharma's prophylactic?

The US FDA's approval on 25 August of Shire's hereditary angioedema (HAE) drug Firazyr (icatibant) as the first and only self-administered subcutaneous treatment for acute attacks has not only opened the gate for the medicine to claim a favourable chunk of the US market in that indication, but also could have an impact on the prophylactic setting.

Metabolic Disorders Immune Disorders

US FDA approves Dyax's Kalbitor for hereditary angioedema

The US FDA has approved Dyax's first drug, Kalbitor (ecallantide), for acute attacks of hereditary angioedema (HAE) in patients aged 16 years and older. The company's Nasdaq share price jumped by more than 20%, to $4.25, on December 2nd on the news.

Gastrointestinal Immune Disorders

FDA approves first drug for acute attacks in HAE patients

The US FDA has approved CSL Behring's Berinert (C1 inhibitor; C1-INH), making it the first treatment approved in the US for acute abdominal attacks and facial swelling associated with hereditary angioedema (HAE). The company plans to launch the drug in December.

Gastrointestinal Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Joshua D Schein, PhD, CEO
    Joe Truitt, VP, Bus. Dev. & Product Strategy
  • Contact Info
  • Lev Pharmaceuticals Inc.
    Phone: (212) 682-3096
    675 3rd Ave.
    22nd Fl.
    New York, NY 10017
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register